301331.SZ
恩威医药
SZSE · C 制造业 · CN
CNY 21.84
−1.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 879.6M | 900.8M | 812.1M | 785.2M | 691.6M |
| Cost of Revenue | 430.5M | 454.8M | 399.4M | 382.7M | 344.4M |
| Gross Profit | 449.1M | 446.0M | 412.7M | 402.5M | 347.1M |
| Operating Expenses | |||||
| R&D Expense | 5.6M | 5.5M | 9.1M | 16.8M | 7.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 68.9M | 69.9M | 76.2M | 59.4M | 59.5M |
| Selling & Marketing Expense | 306.3M | 301.1M | 267.1M | 234.9M | 200.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 391.8M | 387.5M | 363.7M | 315.6M | 276.1M |
| Cost and Expenses | 822.3M | 842.3M | 763.2M | 698.3M | 620.5M |
| Operating Income (EBIT) | 58.3M | 62.4M | 49.7M | 101.7M | 81.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 60.1M | 64.2M | 46.7M | 101.3M | 81.9M |
| Income Tax Expense | 11.9M | 12.2M | 9.2M | 15.0M | 14.1M |
| Bottom Line | |||||
| Net Income | 48.1M | 51.9M | 37.5M | 86.3M | 67.8M |
| Earnings from Cont. Ops | 48.1M | 51.9M | 37.5M | 86.3M | 67.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 48.1M | 51.9M | 37.5M | 86.3M | 67.8M |
| Per Share | |||||
| Basic EPS | CN¥0.47 | CN¥0.50 | CN¥0.37 | CN¥0.84 | CN¥1.19 |
| Diluted EPS | CN¥0.47 | CN¥0.50 | CN¥0.37 | CN¥0.84 | CN¥1.19 |
| Revenue Per Share | CN¥8.55 | CN¥8.75 | CN¥8.07 | CN¥7.64 | CN¥12.14 |
| Shares | |||||
| Basic Shares Outstanding | 102.9M | 102.9M | 100.6M | 102.8M | 57.0M |
| Diluted Shares Outstanding | 102.9M | 102.9M | 100.6M | 102.8M | 57.0M |
| Profitability Metrics | |||||
| EBITDA | — | 113.3M | 101.1M | 143.0M | 119.7M |
| D&A | — | 51.0M | 51.4M | 41.3M | 37.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026